Yasuhiko Kubota1, Lin Y Chen2, Eric A Whitsel3, Aaron R Folsom4. 1. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis. Electronic address: kubot007@umn.edu. 2. Cardiovascular Division, University of Minnesota Medical School, Minneapolis. 3. Department of Epidemiology, Gillings School of Global Public Health and Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill. 4. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis.
Abstract
PURPOSE: The purpose of this study was to estimate the heart rate variability (HRV)-related lifetime cardiovascular disease (CVD) risk. METHODS: We followed 9744 participants without baseline CVD and used a life-table approach to estimate lifetime CVD risk (coronary heart disease, heart failure, and stroke) from 45 through 85 years according to several HRV measures (the SD of RR intervals [SDNN], the root mean square of successive differences of successive RR intervals, the mean of all normal RR intervals [meanNN], low-frequency [LF] and high-frequency [HF] power, and the LF/HF ratio). RESULTS: During 192,110 person-years of follow-up, we documented 2856 CVD events. Cox regression analyses with the false discovery rate method correction showed independent associations of SDNN, meanNN, LF, and LF/HF in women with CVD. Lifetime CVD risks in the lowest compared with the highest tertile were significantly increased in men for LF/HF (51.3% [95% confidence interval, 47.3-54.7] vs. 43.9% [40.1-47.2]), and in women for SDNN (39.4% [36.0-43.0] vs. 29.9% [26.3-33.0]), meanNN (39.3% [35.7-42.7] vs. 28.9% [25.7-31.7]), LF (39.4% [35.9-43.0] vs. 30.0% [26.2-33.2]), and LF/HF (37.6% [33.9-40.9] vs. 30.0% [26.8-32.7]). CONCLUSIONS: Greater HRV was modestly associated with lower lifetime CVD risk.
PURPOSE: The purpose of this study was to estimate the heart rate variability (HRV)-related lifetime cardiovascular disease (CVD) risk. METHODS: We followed 9744 participants without baseline CVD and used a life-table approach to estimate lifetime CVD risk (coronary heart disease, heart failure, and stroke) from 45 through 85 years according to several HRV measures (the SD of RR intervals [SDNN], the root mean square of successive differences of successive RR intervals, the mean of all normal RR intervals [meanNN], low-frequency [LF] and high-frequency [HF] power, and the LF/HF ratio). RESULTS: During 192,110 person-years of follow-up, we documented 2856 CVD events. Cox regression analyses with the false discovery rate method correction showed independent associations of SDNN, meanNN, LF, and LF/HF in women with CVD. Lifetime CVD risks in the lowest compared with the highest tertile were significantly increased in men for LF/HF (51.3% [95% confidence interval, 47.3-54.7] vs. 43.9% [40.1-47.2]), and in women for SDNN (39.4% [36.0-43.0] vs. 29.9% [26.3-33.0]), meanNN (39.3% [35.7-42.7] vs. 28.9% [25.7-31.7]), LF (39.4% [35.9-43.0] vs. 30.0% [26.2-33.2]), and LF/HF (37.6% [33.9-40.9] vs. 30.0% [26.8-32.7]). CONCLUSIONS: Greater HRV was modestly associated with lower lifetime CVD risk.
Authors: Emily B Schroeder; Lloyd E Chambless; Duanping Liao; Ronald J Prineas; Gregory W Evans; Wayne D Rosamond; Gerardo Heiss Journal: Diabetes Care Date: 2005-03 Impact factor: 19.112
Authors: Emily B Schroeder; Eric A Whitsel; Gregory W Evans; Ronald J Prineas; Lloyd E Chambless; Gerardo Heiss Journal: J Electrocardiol Date: 2004-07 Impact factor: 1.438
Authors: Evgenia Gourgari; Jeanette M Stafford; Ralph D'Agostino; Lawrence M Dolan; Jean M Lawrence; Amy Mottl; Catherine Pihoker; Elaine M Urbina; R Paul Wadwa; Dana Dabelea Journal: Ann Pediatr Endocrinol Metab Date: 2019-09-30
Authors: Maryse J Bakema; Mirjam van Zuiden; Didier Collard; Jasper B Zantvoord; Susanne R de Rooij; Leonie K Elsenburg; Marieke B Snijder; Karien Stronks; Bert-Jan H van den Born; Anja Lok Journal: Front Psychiatry Date: 2020-03-17 Impact factor: 4.157
Authors: Regina von Rennenberg; Thomas Krause; Juliane Herm; Simon Hellwig; Jan F Scheitz; Matthias Endres; Karl Georg Haeusler; Christian H Nolte Journal: Front Neurol Date: 2021-12-23 Impact factor: 4.003
Authors: Noortje G Godijk; Alinda G Vos; Vita W Jongen; Robert Moraba; Hugo Tempelman; Diederick E Grobbee; Roel A Coutinho; Walter Devillé; Kerstin Klipstein-Grobusch Journal: Glob Heart Date: 2020-02-12
Authors: Aaron R Folsom; Pamela L Lutsey; Zachary C Pope; Oluwaseun E Fashanu; Jeffrey R Misialek; Mary Cushman; Erin D Michos Journal: Res Pract Thromb Haemost Date: 2019-12-13